건강 보도자료
-
- MicroVention Rebrands to Terumo Neuro - Reflects Expanded Focus and Strategic Growth
- MicroVention, Inc., a global leader in neurovascular innovation and a wholly owned subsidiary of Terumo Corporation, today announced its official rebranding to Terumo Neuro, effective immediately. This name change signifies a new chapter in the co...
- 15:35
-
- ITM Obtains Exclusive Worldwide License from Debiopharm for CA IX-Targeted Peptide-based Radiopharmaceutical Programs Targeting Solid Tumors
- ITM Isotope Technologies Munich SE (ITM) , a leading radiopharmaceutical biotech company and Debiopharm , a Swiss-based, global biopharmaceutical company, aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases, toda...
- 14:30
-
- Neuraptive Therapeutics Receives FDA Breakthrough Therapy Designation for NTX-001 and Provides Update on the Advancements of NTX-001 for the Treatment of Peripheral Nerve Injury Requiring Repair
- Neuraptive Therapeutics, Inc. today announced that NTX-001 has been granted Breakthrough Therapy Designation, thus providing the potential for accelerated development for patients with peripheral nerve injury requiring repair. This designation fol...
- 13:40
-
- Novotech Unveils 2024 Report on Global Gastric Cancer Clinical Trials and Cutting-Edge Therapeutics
- Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel therapeutics at every phase, has released its latest industry report, Gastric ...
- 11:50
-
- Novotech Wins Prestigious Brandon Hall Gold Award for CRA Monitoring Simulation Program under the category of Best Competencies and Skill Development
- Novotech, a leading full-service clinical Contract Research Organization (CRO), is proud to announce that its Clinical Research Associate (CRA) Monitoring Simulation Program has been recognized with the Brandon Hall Gold Award in the category of B...
- 09:55
-
- Merck Unveils New MAVENCLAD® Four-Year Data Highlighting Benefits of Early Treatment and Sustained Efficacy Across Multiple Measures of Disease Activity
- Not intended for UK-, US- or Canada-based media Merck, a leading science and technology company, today announced presentations showcasing the long-term safety profile, sustained efficacy data, and durable effect of MAVENCLAD® (cladribine tablets) ...
- 08:55
-
- Novotech Appoints Dr. Yooni Kim as a New Executive Position of Managing Director for APAC to Strengthen Global Expansion
- Novotech, the leading global biotech Contract Research Organization (CRO), is pleased to announce the appointment of Dr. Yooni Kim as a new Executive position of Managing Director for the Asia-Pacific (APAC) region, effective September 1, 2024. Th...
- 09월 12일 13:50
-
- Novotech Honored with Frost & Sullivan’s 2024 Best Practices Company of the Year Award for Leadership in Biotech CRO Services
- Novotech, the global full-service clinical Contract Research Organization (CRO), is proud to announce that it has been awarded the prestigious 2024 Global Company of the Year Award by Frost & Sullivan. This recognition underscores Novotech’s commi...
- 09월 11일 17:20
-
- CorFlow Therapeutics AG Completes €44 Million Series B Financing to Support the Advancement of a Novel Diagnostic and Drug Delivery Platform for Microvascular Obstruction (MVO) in Heart Attack Patients
- CorFlow Therapeutics AG (CorFlow) announced today that it has raised €44 million in Series B funding, co-led by Broadview Ventures and Panakes Partners with strong continued support from 415 Capital , CorFlow's initial VC investor and largest shar...
- 09월 11일 11:05
전시회
